Indivior Pharmaceuticals (INDV) Return on Capital Employed (2025 - 2026)
Indivior Pharmaceuticals' (INDV) quarterly Return on Capital Employed came in at 79.29% in Q1 2026, up 7077.0% year-on-year from 1.1% in Q1 2025, and up 19.38% quarter-over-quarter from 66.41% in Q4 2025.
Indivior Pharmaceuticals (INDV) Return on Capital Employed (2025 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Return on Capital Employed history runs 2 years deep, the most recent figure standing at 79.29% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 7077.0% year-over-year to 79.29% in Q1 2026; TTM through Mar 2026 was 79.29%, a 7077.0% increase from a year earlier, with the FY2025 full-year figure at 76.05%, up 6985.0% from the prior year.
- Return on Capital Employed rose to 79.29% in Q1 2026 per INDV's latest filing, from 66.41% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 79.29% in Q1 2026 and bottomed at 8.52% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Indivior Pharmaceuticals | 1.00 Bn | 829.65 Mn | 277.00 Mn | 79.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79.29% |
| Dec 31, 2025 | 66.41% |
| Sep 30, 2025 | 48.40% |
| Jun 30, 2025 | 61.26% |
| Mar 31, 2025 | 8.52% |